Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research ›› 2020, Vol. 4 ›› Issue (1-2): 200013-200013.DOI: 10.21127/yaoyimr20200013

Special Issue: Nanomedicine

• Perspective • Previous Articles     Next Articles

Prodrug Systems (I): Lipid-Based Doxorubicin Prodrugs and Their Nanodelivery Systems

Filipe Olim,a Ana Rute Neves,a Zhao Wang,b Jingjing Sun,c Helena Tomás,*,a and Ruilong Sheng*,a   

  1. a CQM - Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal;
    b School of Material Engineering, Jinling Institute of Technology, Nanjing, Jiangsu 211169, China;
    c Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States
  • Received:2020-05-15 Revised:2020-06-08 Online:2020-06-10 Published:2020-06-16
  • Contact: Email: lenat@staff.uma.pt (H. T.), ruilong.sheng@staff.uma.pt (R. S.)
  • Supported by:

Abstract: Using natural lipids to covalently connect with antitumor agents to construct lipid-based molecular prodrugs and their nanosystems is a promising research frontier for sustainable medicinal chemistry, nanobiotechnology and tumor chemotherapy. This paper reviewed recent progress of lipid-based doxorubicin (molecular) prodrugs and their nanodelivery systems, including lipid-doxorubicin prodrugs, stimuli-responsive lipid-doxorubicin prodrugs, and lipid-doxorubicin prodrug-based drug co-delivery nanosystems. Additionally, possible future research outlooks in this field were also discussed.


Key words: lipid, doxorubicin, prodrugs, stimuli-responsive, drug co-delivery, nanosystems

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States